Urinary excretion and serum concentration of mevalonic acid during acute intake of alcohol

Metabolism: Clinical and Experimental

Volumn 49, Issue 1, 2000, Pages 62-66

  Lindenthal, Bernhard ^a   Von Bergmann, Klaus ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LATHOSTEROL; MEVALONIC ACID;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BEER; BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0033964486     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(00)90713-3     Document Type: Article

References (27)

1. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343:425-430, 1990
2. Parker TS, McNamara DJ, Brown C, et al: Mevalonic acid in human plasma: Relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Nati Acad Sci USA 79:3037-3041, 1982
3. Lindenthal B, Simatupang A, Dotti MT, et al: Urinary excretion of mevalonic acid as an indicator of cholesterol synthesis. J Lipid Res 37:2193-2201, 1996
4. Parker TS, McNamara DJ, Brown CD, et al: Plasma mevalonate as a measure of cholesterol synthesis in man. J Clin Invest 74:795-804, 1984
5. Pappu AS, Illingworth DR: Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia. J Lab Clin Med 114:554-562, 1989
6. Naoumova RP, Cummings MH, Watts GF, et al: Acute hyperinsulinaemia decreases cholesterol synthesis less in subjects with non-insulindependent diabetes mellitus than in non-diabetic subjects. Eur J Clin Invest 26:332-340, 1996
7. Naoumova RP, Dunn S, Rallidis L, et al: Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res 38:1496-1500, 1997
8. Popjak G, Boehm G, Parker TS, et al: Determination of mevalonate in blood plasma in man and rat. Mevalonate "tolerance" tests in man. J Lipid Res 20:716-728, 1979
9. Eskelson CD, Cazee CR, Anthony W, et al: In vitro inhibition of cholesterolgenesis by various thyroid hormone analogs. J Med Chem 13:215-220, 1970
10. Cronholm T, Burlingame AL, Sjovall J: Utilization of the carbon and hydrogen atoms of ethanol in the biosynthesis of steroids and bile acids. Eur J Biochem 49:497-510, 1974
11. Lefevre AF, DeCarli LM, Lieber CS: Effect of ethanol on cholesterol and bile acid metabolism. J Lipid Res 13:48-55, 1972
12. Lakshmanan MR, Veech RL: Measurement of rate of rat liver sterol synthesis in vivo using tritiated water. J Biol Chem 252:4667-4673, 1977
13. Crouse JR, Grundy SM: Effects of alcohol on plasma lipoproteins and cholesterol and triglyceride metabolism in man. J Lipid Res 25:486-496, 1984
14. Lindenthal B, von Bergmann K: Determination of urinary mevalonic acid using isotope dilution technique. Biol Mass Spectrom 23:445-450, 1994
15. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
16. Czubayko F, Beumers B, Lammsfuss S, et al: A simplified micro-method for quantification of fecal excretion of neutral and acidic sterols for outpatient studies in humans. J Lipid Res 32:1861-1867, 1991
17. Skeggs HR, Wright LD, Cresson EL, et al: Discovery of a new acetate-replacing factor. J Bacteriol 72:519-524,1956 (abstr)
18. Bjorkhem I, Miettinen T, Reihner E, et al: Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. J Lipid Res 28:1137-1143, 1987
19. Roullet JB, Xue H, Pappu AS, et al: Mevalonate availability and cardiovascular functions. Proc Natl Acad Sci USA 90:11728-11732, 1993
20. Roullet JB, Xue H, Roullet CM, et al: Mevalonate availability affects human and rat resistance vessel function. J Clin Invest 96:239-244, 1995
21. Roullet JB, Xue H, Chapman J, et al: Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J Clin Invest 97:2384-2390, 1996
22. Scoppola A, De Paolis P, Menzinger G, et al: Plasma mevalonate concentrations in uremic patients. Kidney Int 51:908-912, 1997
23. Subang MC, Stewart Phillips JL, Pappu AS, et al: Possible role of mevalonate in the hypercholesterolemia seen in experimental chronic renal failure. Nephron 69:151-154, 1995
24. Al Shurbaji A, Humble E, Rudling M, et al: Hepatic cholesterol metabolism in experimental nephrotic syndrome. Lipids 33:165-169, 1998
25. Lala A, Scoppola A, Motti C, et al: Apolipoprotein E genotype and cholesterogenesis in polygenic hypercholesterolemia. Metabolism 47:97-100, 1998
26. Shoda J, Miyamoto J, Kano M. et al: Simultaneous determination of plasma mevalonate and 7 alpha-hydroxy-4-cholesten-3-one levels in hyperlipoproteinemia: Convenient indices for estimating hepatic defects of cholesterol and bile acid syntheses and biliary cholesterol supersaturation. Hepatology 25:18-26. 1997
27. Hoffmann GF, Charpentier C, Mayatepek E, et al: Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 91:915-921, 1993